Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies

Abstract: Strategies to enhance the already established doublet chemotherapy regimen for lung cancer have been investigated for more than 20 years. Initially, the concept was to administer chemotherapy drugs locally to the tumor site for efficient diffusion through passive transport within the tumor. Recent advances have enhanced the diffusion of pharmaceuticals through active transport by using pharmaceuticals designed to target the genome of tumors. In the present study, five patients with non-small cell lung cancer epidermal growth factor receptor (EGFR) negative stage IIIa–IV International Union Against Cancer 7 (UICC-7), and with Eastern Cooperative Oncology Group (ECOG) 2 scores were administered platinum-based doublet chemotherapy using combined intratumoral-regional and intravenous route of administration. Cisplatin analogues were injected at 0.5%–1% concentration within the tumor lesion and proven malignant lymph nodes according to pretreatment histological/cytological results and the concentration of systemic infusion was decreased to 70% of a standard protocol. This combined intravenous plus intratumoral-regional chemotherapy is used as a first line therapy on this short series of patients. To the best of our knowledge this is the first report of direct treatment of involved lymph nodes with cisplatin by endobronchial ultrasound drug delivery with a needle without any adverse effects. The initial overall survival and local response are suggestive of a better efficacy compared to established doublet cisplatin–based systemic chemotherapy in (higher) standard concentrations alone according to the UICC 7 database expected survival. An extensive search of the literature was performed to gather information of previously published literature of intratumoral chemo-drug administration and formulation for this treatment modality. Our study shows a favorable local response, more than a 50% reduction, for a massive tumor mass after administration of five sessions of intratumoral chemotherapy plus two cycles of low-dose intravenous chemotherapy according to our protocol. These encouraging results (even in very sick ECOG 2 patients with central obstructive non-small cell lung cancer having a worse prognosis and quality of life than a non-small cell lung cancer in ECOG 0 of the same tumor node metastasis [TNM]-stage without central obstruction) for a chemotherapy-only protocol that differs from conventional cisplatin-based doublet chemotherapy by the route, target site, and dose paves the way for broader applications of this technique. Finally, future perspectives of this treatment and pharmaceutical design for intratumoral administration are presented.

Keywords: cisplatin, lymph nodes, chemotherapy, intratumoral, lung cancer

Introduction

Lung cancer treatment still remains a challenge. In the last decade an effort has been made to identify the mechanisms and pathways of lung cancer.\(^1,2\) Pharmacoeconomics in association with pharmacoconomics has also been investigated as the genetic mutations of lung cancer differ among populations and therefore several
targeted therapies present a higher rate of efficiency, as is the case with epidermal growth factor receptor mutation (EGFR).\textsuperscript{3–5} Pharmacogenetics have also been investigated for conventional chemotherapy in lung cancer in an effort to identify different pathways and mechanisms of acquired resistance to conventional chemotherapy.\textsuperscript{6–7} Targeted therapies have been approved as first line treatment for specific genetic mutations and many pathways are still under investigation.\textsuperscript{8} However, doublet chemotherapy still remains the cornerstone of treatment for many patients.\textsuperscript{9}

Chemotherapy drugs present non-specific cytotoxic activity, which in many cases induce adverse effects from systemic administration. Patients have to stop their treatment and the national health systems are affected by the additional hospitalization days and drugs administered.\textsuperscript{10} In an effort to enhance the efficiency of conventional chemotherapy, several studies have investigated the addition of immunomodulatory agents with conventional chemotherapy and/or anti-vascular endothelial growth factors with targeted chemotherapy.\textsuperscript{11–14} However, systemic side effect prevalence still remains the same.

Another conceptual approach, ie, the locoregional administration of chemotherapeutics has been promoted by many groups either in the form of intratumoral chemotherapy (ITC),\textsuperscript{15–17} brachytherapy,\textsuperscript{18} photodynamic therapy,\textsuperscript{19} mechanic debulking,\textsuperscript{20,21} and aerosol chemotherapy.\textsuperscript{22–24} Locoregional therapy uses chemicals, genes, biologics, free or formulated drugs, and novel drug carrier systems, as a single therapy or with radiation therapy,\textsuperscript{25–29} thermal,\textsuperscript{22,24} or non-thermal local ablative methods. These studies were mostly intended to establish the safety and efficacy of locoregional therapies and investigate whether higher drug concentration could increase efficiency and decrease or prevent systemic adverse effects. Intratumoral drug administration was also investigated as a method to sensitize the tumor to radiotherapy and systemic chemotherapy.\textsuperscript{30} Nearly 30% of newly diagnosed patients with lung cancer will develop respiratory distress, bleeding, atelectasis, and post-obstructive pneumonia due to partial or complete airway obstruction.\textsuperscript{31} The tumor core consists of chemotherapy resistant tumor cells and intratumoral chemotherapy has been observed to sensitize these cells by delivering selected drugs into different parts of the core with radioactive coils and other agents for brachytherapy.\textsuperscript{30,32–34} In particular, it was observed that nanocarriers for chemotherapy drugs lead to improved drug diffusion and sustain release. In addition, brachytherapy studies presented data were the radiation emitted from the coils was only cytotoxic to the site of implantation.\textsuperscript{30,35} It has also been observed that local tumor response is accomplished more quickly with local intratumoral drug administration.\textsuperscript{16,36}

Moreover, there are obstacles that have to be bypassed with these treatment techniques, such as: (a) increased interstitial fluid pressure, (b) local hypoxia, (c) heterogeneous distribution of drug formulations due to abnormal vascular architecture, (d) extracellular matrix with collagen, elastin, fibroblasts, and (e) structural abnormalities within the center of the tumor. There are two principal methods of drug permeation of the tumor as a sum effect of diffusion and distribution within the tumor: active and passive transportaion, which can be combined with a physical (pre)treatment, like heating the device to enhance uptake or diffusion,\textsuperscript{37–39} or with a cooling device.\textsuperscript{40} Several formulations have been investigated either with passive or active transportation in order to investigate their efficiency. In addition, carriers have been added to several pharmaceuticals to prolong their local release and diffusion rates.\textsuperscript{41,42} Nanocarriers have provided an effective method for drug accumulation within the tumor due to the enhanced permeability and retention effect (EPR) effect.\textsuperscript{43} The EPR effect has been also observed to be enhanced with the addition of polyethylene glycol (PEG) stealth molecules,\textsuperscript{44} and controlled by heat shock protein 32 and carbon monoxide.\textsuperscript{45} The present study illustrates our initial experience with intratumoral chemotherapy compared to previous published studies and we propose future avenues for applications of this methodology.

Patients and methods

Patients and study design

Five patients stage IIIa–IV, performance status 2 (PS2) unfit for surgery, radiation, and chemotherapy were included in the trial. The trial was initiated in May 2009 and was approved by our investigational review board (IRB; Table 1). One additional patient was excluded from the trial when she was diagnosed with mammalian carcinoma stage IV with a stenotic tracheal metastasis and hypercapnia $\geq 60$ mmHg unfit for treatment with laser or argon-plasma-coagulation or radiation; however, she was treated along the same line of this protocol only with slightly different ITC mixture, adding 2 mg mitomycin to 10 mg cisplatin, and observed upon follow up. The staging was decided according to the sixth edition of tumor node metastasis (TNM) classification of non-small cell lung cancer (NSCLC) as the trial took place in 2009 and 2010. All patients had relatively adequate renal function allowing for the administration of at least 70% of the dose defined intravenous standard platinum doublet protocol (or alternatively area under the curve [AUC] 4 in case of carboplatin; defined by a level of serum creatinine of Value1.5 mg/mL), hepatic enzymes (bilirubin
Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Patient stage</th>
<th>ECOG</th>
<th>Local 4-week response</th>
<th>Survival (days)</th>
<th>Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. IIIb (cT4N2Mx)</td>
<td>2</td>
<td>PR–</td>
<td>311</td>
<td>Squamous</td>
</tr>
<tr>
<td>2. IV (cT3-4NxM1b)</td>
<td>2</td>
<td>PR+</td>
<td>429</td>
<td>Squamous</td>
</tr>
<tr>
<td>3. IIIb (cT4N2M0)</td>
<td>2</td>
<td>PR–</td>
<td>496*</td>
<td>Squamous</td>
</tr>
<tr>
<td>4. IV (cT3-4N2M1b)</td>
<td>2</td>
<td>PR+</td>
<td>365</td>
<td>Adeno</td>
</tr>
<tr>
<td>5. Ila (cT4N1M0)</td>
<td>2</td>
<td>NC</td>
<td>552*</td>
<td>Adeno</td>
</tr>
<tr>
<td>6. Mammarian</td>
<td>2</td>
<td>Local CR</td>
<td>319</td>
<td>Adeno</td>
</tr>
</tbody>
</table>

Notes: *Alive upon end of follow-up, other patients died due to cancer-related death. Average PR+: overall survival: 463 days; average PR–: overall survival: 338 days. PR+: reduction of >50% of initial volume; PR–: reduction of 25%–50% of initial volume.

Expected median survival according to UICC 7 in ECOG 0–1 patients: Ila 1/5, IIlb 2/5, IV 2/5 = (1(114 m) + (210 m) + (245 m))/5 = 9.2 months = 276 days.

Achieved median survival in this ECOG 2 group along our protocol = 13.2 m = 397 days: This means a surplus of 43.8% median survival in comparison to expected survival.

Abbreviations: PR, partial response; ECOG, Eastern Cooperative Oncology Group; NC, no change; CR, complete response; Adeno, adenocarcinoma; CA, carcinoma.

of Value 1.5 mg/dL), and hematologic function (absolute neutrophil count of 1.5 × 10^9 mm^3) and platelet count of 1.0 × 10^5 mm^3). Patients included had symptomatic obstruction of the trachea or of a major bronchus secondary to inoperable histologically confirmed NSCLC. The patient population in this study included only patients with disease confined to one hemithorax and with the major tumor involvement in the thorax. Two cases with Stage IV NSCLC showed single bone metastasis in upper arm respectively in thigh. For such cases, the therapeutic strategy was to relieve symptoms from the bronchial tumor and to address metastatic bone deposit with radiation therapy and bisphosphonates according to standard oncologic care. Nearly complete airway obstruction, superior to 50% occlusion of at least one major airway was required for inclusion into the study. Other criteria were: isolated lobar obstruction was included only if it was believed to contribute to respiratory insufficiency, chronic (or continuous) bleeding worsening the respiratory situation or post-obstructive pneumonia, or all these conditions together. Patients with small cell carcinoma were excluded, based on anticipated rapid response to systemic chemotherapy or irradiation or both that these patients often experience.46

All patient treatment sessions were recorded in order to evaluate the therapeutic protocol (Figures 1–6). Criteria for exclusion were: pregnancy or child-bearing potential without using contraceptive methods, concurrent highly septic situations due to poststenotic pneumonia infections (ie, requiring intravenous antibiotic therapy was allowed), an unstable or serious concurrent medical condition (eg, recent myocardial infarction and superior vena cava syndrome), recent major surgery, or large-field radiation therapy or chemotherapy in the month before entry. Patients were not allowed to receive any concurrent radiotherapy to the lungs, immunotherapy or investigational agents while on the study. These criteria were chosen based on previous publications (Table 2).16,47 Written informed consent was obtained from each patient before study enrollment. Patient characteristics upon admission are presented in Table 1.

Dose schedule and technical aspects

The protocol was based on previous publications in the field of intratumoral chemotherapy.16,36,46–48 Previous groups treated their patients with cisplatin 0.5%–4% ITC. In Germany, 0.5% cisplatin is the concentration for intravenous administration; although uncommon, other cisplatin concentrations are available through the hospital’s dispensary when buying cisplatin as a salt. It is believed that upon intratumoral bolus injection, cisplatin will diffuse systemically via lymphatic draining vessels and lymph nodes; such drainage may reach sentinel lymph nodes that would be exposed to the drug as a consequence of ITC and at a higher drug concentration than possible with intravenous administration of the same cisplatin amount (Figure 5).

Figure 1 X-ray from patient 1.

Notes: (A) X-ray upon diagnosis. (B) after one session (1 month). (C) and after two sessions (6 weeks after diagnosis).
As lymph node involvement in lung cancer is a major concern for local recurrence, we added the direct treatment of involved lymph nodes by drug delivery through a transbronchial needle aspiration (TBNA)-needle of an endobronchial ultrasound (EBUS)-probe to enhance the efficacy over ITC only. This drug delivery by an EBUS-needle (EBUS-transbronchial needle dosing [TBND]) is aiming at six passes per lymph node to optimize the permeation of the drug. We have chosen this number as six passes are the optimal number for EBUS-TBNA to get representative results of the whole lymph node volume.

A huge point of contention for the use of ITC is the under or over-dosing due to the leakage or backflow of drug. Such “loss” if not quantified makes it very difficult to relate the dose to the effect over a tumor or target volume unit. We think that even in the case that intratumoral-volume leaks out of the tumor very easily as a so called “downstream effect”, this intratumoral-loss cisplatin dose will be reabsorbed by the alveoli and mucosa in other lung areas and will act as a systemic administration. In other words, ITC that uses aqueous platinum analog offers the advantage of very high concentrations (eg, up to 70-fold higher compared to the same amount of carboplatin given intravenously in ITC with polyethylene glycol (PEG)-carboplatin) with less systemic cytotoxicity but in the end it resembles an established intravenous split schedule: the timely separation of intratumoral and intravenous administration leads to the well-known efficient intravenous split cisplatin protocols with two dosages typically 6 to 7 days apart and therefore this dosing regimen makes sense.

ITC has been demonstrated in animal models with lung cancer to induce a positive antitumor immunoresponse; meaning a significant reduction in tumor mass different than the main site directly treated by ITC. The same has
been proven in human beings using other local treatment modalities in different cancers. This effect is believed or has been partly proven to be caused by demonstrating vast amounts of tumor cell debris toward immunocompetent cells, which are stimulating the immune system to use these “specific” antigens to induce a “specific” antibody reaction; eg, auto-vaccination triggered by local treatment modalities. The cornerstone of these mechanisms is an intact competent immune system which could be negatively influenced by acute administration of intravenous chemotherapy. This is the second reason to separate intravenous from intratumoral administration timing for the first 5–10 days of treatment.

A major factor affecting ITC-efficacy is the distribution of the drug intratumorally. We treated the mass from all possible directions: from endoluminal or from transthoracical direction if feasible under ultrasound or C-arm fluoroscopy guidance due to local anatomy. We used direct central needle insertion in lobar stenosis (with atelectasis, chronic bleeding, and/or post-stenotic pneumonia) and in central airway stenosis with a transmucosal part of bulk and/or involved lymph nodes we treated this part of the tumor by EBUS-TBND. In lymph nodes, we aimed at six passes with different angulations for EBUS-TBND. For masses that abutted the thoracic wall, we used ultrasound guided percutaneous transthoracic drug injection (transthoracic ultrasound [tts] ITC) through only one transthoracic puncture receiving the needle tip to the most distal part of the ultrasound picture of the mass and injecting 1 mL ITC-drug after each 0.5 cm pulling step back toward the puncture point. This procedure was repeatedly performed in different angulations with 30 degrees difference in a three-dimensional manner and under bronchoscopy for controlling and calculating the “loss” amount of ITC leaking out of tumor mass and dispersing rapidly down toward the central airways – the so called downstream effect of ITC. The downstream effect may result from the typically inhomogeneous spongy tumor structure or separated by septa, layers, or from puncturing of bronchioli lumen still patent within the tumor. In order to better visualize the downstream effect, we colored the cisplatin-ITC with indigo Carmine dye (0.5 mL/10 mL drug volume). If a downstream effect occurred, the injection was stopped, the needle position was changed by retracting 1 cm, followed by the next injection of 1 mL until the subpleural area adjacent to the insertion point was reached. Then a new needle pathway with different angulations was started at the most distal point of the ultrasound picture. In case visualization by ultrasound was not possible we used different angulations under c-arm fluoroscopy control. All this was to achieve a best individual distribution of the ITC-drug to cover up the major part of the tumor volume and involved lymph nodes.

Furthermore, the calculation of the ITC-drug volume was done along the lines of the formula by Monga using the help of the computed tomography (CT)-scans (in mL ITC-drug):

\[
\text{Volume} = 0.5 \times \text{maximum height} \times \text{maximum width} \times \text{maximum depth}
\]

covering approximately 1 mL of tumor with 1 mL of ITC-drug. In this study, we were adding the volume for
involved lymph nodes which were measured by EBUS during the diagnostic TBNA in addition to the CT-scans prior to therapy. In case a downstream effect was observed, we summed up each observed 1 mL (meaning suddenly rapid unmeasured droplets) of "lost" ITC-drug after planned injection of 1 mL ITC and added this amount afterwards to another “additional” path with a different angulation until the pre-therapeutic calculated ITC-volume was reached. The consequence of this approach was that in the patients with a downstream effect more ITC-volume than previously calculated was used. In reality, this was observed in two patients with no more than 10% additional volume only in the transthoracical approach. We restricted ourselves to a maximum of total ITC volume 2-fold of the pre-therapeutic calculated ITC-volume. A CT-scan for reevaluation and recalculation of the ITC-volumes was repeated after two complete intravenous cycles encompassed by four to six administrations of ITC. The minimal goal in these very sick patients

<table>
<thead>
<tr>
<th>Author</th>
<th>Methodology</th>
<th>Subjects</th>
<th>Cancer cells/tissue</th>
<th>Response</th>
<th>Nanoparticles</th>
<th>Carriers</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jia et al</td>
<td>Intratumoral plus doxorubicin magnetic field</td>
<td>In vitro/in vivo</td>
<td>Lewis lung cancer</td>
<td>√</td>
<td>Magnetic Fe₃O₄</td>
<td>PLGA</td>
<td>27</td>
</tr>
<tr>
<td>Akeda et al</td>
<td>OK-432</td>
<td>In vivo</td>
<td>Squamous lung carcinoma</td>
<td>√</td>
<td>–</td>
<td>–</td>
<td>80</td>
</tr>
<tr>
<td>Li et al</td>
<td>Multifunctional theranostic liposome drug delivery system plus doxorubicin</td>
<td>In vitro/in vivo</td>
<td>Squamous cell carcinoma-4 tumor cells</td>
<td>√</td>
<td>Magnetic</td>
<td>Liposomes</td>
<td>62</td>
</tr>
<tr>
<td>Celikoglu et al</td>
<td>5-fluorouracil, mitomycin, methotrexate, bleomycin, mitoxantrone, cisplatin</td>
<td>Patients</td>
<td>Lung cancer</td>
<td>√</td>
<td>–</td>
<td>–</td>
<td>16</td>
</tr>
<tr>
<td>Fujinara et al</td>
<td>Intratumoral-PS3</td>
<td>Patients</td>
<td>Lung cancer</td>
<td>√</td>
<td>–</td>
<td>–</td>
<td>25</td>
</tr>
</tbody>
</table>

**Abbreviations:** OK, lyophilized incubation mixture of group A Streptococcus pyogenes of human origin; PLGA, poly(lactic-co-glycolic acid).

### Table 3 Effects and safety features

<table>
<thead>
<tr>
<th>Patient</th>
<th>Adverse effect</th>
<th>Positive effect</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Enforced bleeding after 1 ITC (infiltration of the LLL-vein)</td>
<td>Stopped moderate chronic bleeding after second ITC, no recurrence of bleeding.</td>
<td>PR– (main symptom was bleeding).</td>
</tr>
<tr>
<td>2</td>
<td>Vomiting, nausea, and hematotoxicity. (1800 Leuc./µL) after first ITC with 100 mg cisplatin</td>
<td>Could swallow again after second ITC stopping muscle waste, walks alone.</td>
<td>PR+: possible infiltration of the esophagus in reference to thorax-CT. Hematotoxicity as a proof of systemic effect.</td>
</tr>
<tr>
<td>3</td>
<td>None</td>
<td>Relief of dyspnoea and mucous retention, stopped chronic bleeding after first ITC.</td>
<td>PR+</td>
</tr>
<tr>
<td>4</td>
<td>None</td>
<td>Relief of retention, reduced pCO₂.</td>
<td>PR–; heavy smoker until death.</td>
</tr>
<tr>
<td>5</td>
<td>Acute cytotoxicity in the complete ROL as COP (including S3) radiological without clinical relevance and spontaneous regression without any lasting damage; needle was steered from inside at the inner 2/3 margin of the lobar atelectasis which occluded orifice S1+S2 in ROL.</td>
<td>None (slightly less back pain).</td>
<td>NC</td>
</tr>
<tr>
<td>6</td>
<td>Fever for 3 days after ITC.</td>
<td>Local CR, no longer bleeding or retention.</td>
<td>Local CR; acute short mediastinitis? Breast cancer stage IV with tracheal metastasis (out of protocol).</td>
</tr>
</tbody>
</table>

**Abbreviations:** CT, computed tomography; ITC, intratumoral chemotherapy; CR, complete response; COP, cryptogenic organising pneumonia; Leuc, leucocytes; ROL, right upper lobe (rul); PR, partial response; pCO₂, partial carbondioxide measurement; LLL, left lower lobe; S, subsegment; NC, no change.
was to administer two cycles intravenous platinum doublet every 3–4 weeks encompassed with at least four sessions ITC. We hoped to achieve four cycles intravenous doublet encompassed by 8–12 ITC-administrations timely separated as mentioned above if the patient was willing to do so and if the local (meanwhile regressed) anatomy was feasible to inject. One potential limitation of this protocol was the fact that these sick patients had to be treated weekly for the ITC-administration with aqueous cisplatin. In palliative patients, too much time inside the hospital should be avoided.

Previous experience of intratumoral administration was 30–40 mg aqueous cisplatin demonstrating good tumor reduction and no adverse effects. \(^{16,36,46–48}\) Therefore we used cisplatin 1% for smaller masses and 0.5% cisplatin concentration for larger masses to realize a compromise between injected volume and drug amount per tumor volume unit for optimization of drug distribution and tumor coverage with ITC. It has to be mentioned that it was allowable to use more than 40 mg cisplatin per ITC-session, but not more than the (theoretical) 70% standard cisplatin intravenous amount in these very sick patients. We restricted ourselves therefore to the maximal dose of 100 mg cisplatin per ITC-session. In reality, this was only used in one ITC-session, all other ITC-sessions were done with 10–50 mg cisplatin in total (average 24 mg cisplatin).

The drug injection rate for ITC was between 1 and 5 mL/minute: if the downstream effect occurred we stopped injection at the preceding injection point and reduced our velocity to 1 mL/minute at the next injection point after retraction of the needle. If there was no downstream effect with 1 mL/minute in the preceding injection point we elevated our injection velocity to 5 mL/minute in the following injection point after retraction. All this was meant to optimize the coverage of ITC-volume in the mass and the time per treatment session. The treatment times for an ITC-session covering tumor mass and node(s) (average mass dimensions: 7 cm; average number of nodes: 2) was between 25 and 60 minutes (average 38 minutes).

**Pharmaceuticals**

The following pharmaceuticals were used for weekly intratumoral chemotherapy 5–10 days apart from the intravenous administration: cisplatin/hospira solution for infusion 100 mg/100 mL vial BT × 1 vial × 100 mL (Hospira UK Ltd, Queensway, Royal Leamington Spa, Warwickshire, UK) in concentrations between 0.5% and 1%.

For intravenous chemotherapy, 70% of a standard platinum analog containing doublet scheme repeating every 3–4 weeks with the following drugs was used: cisplatin or carboplatin and one of the following drugs GEMZAR\(^{\text{a}}\) (Lilly USA LLC, Indianapolis, IN, USA; 200 mg/1 g vial), etoposide, and vincristine.

The intravenous administration was separated from ITC by 5–10 days. The protocol aimed to treat these very sick patients was with at least two cycles of intravenous administration encompassed by 4–6 intratumoral administrations, if feasible due to local anatomy. The intravenous combination scheme was chosen based on the performance status of the patients. Putting intravenous and intratumoral administrations together means that between two intravenous administrations it was possible to give an additional two or three ITC-administrations (Figure 6).

**Specific treatment effects and complications**

In summary, there was no severe adverse event in a total of 22 ITC-sessions even in an ITC with 100 mg cisplatin showing only a one-time moderate hematotoxicity with 1800 leukocytes/mL. This is striking as a proof of the concept that ITC either passed through the lymphatic vessels or was downstreamed or reabsorbed by the bronchial mucosa and alveoli to become systemically active. It is worth mentioning that for all directly visible tumor masses the first injection with ITC, regardless of the approach (endoluminal or transthoracic), changed the tumor color to pale or white almost immediately and sometimes after the injection of only 1 mL. This appears to be an acute interruption of the perfusion or a “shock reaction” of the tumor. Another interesting observation was the fact that in patients with chronic bleeding from the tumor or from peritumoral vessels, the bleeding stopped after only one or two ITC-sessions. No acute local toxic effect in the mucosa or in the healthy central airways could be identified; no late stenotic process after ITC-sessions occurred either. Similar findings have been reported in previous studies (Table 1). \(^{16,36,46–48}\)

**Discussion**

Intratumoral injection of chemotherapeutics is an efficient and safe local therapeutic method. ITC as adjuvant therapy using the protocol described herein showed, as in other ITC-studies, an expected relief concerning the acute local problems caused by stenosis, bleeding, or atelectasis in four of five NSCLC patients in the protocol and in one patient (out of protocol) with mammalian cancer and tracheal metastasis. \(^{32,42,44,54–60}\) Moreover, this trial demonstrated for the first time that direct treatment of involved lymph nodes with ITC by aqueous cisplatin simultaneously to the tumor mass is possible and safe. As the results concerning debulk-
ing are similar to those of other studies, loss of ITC-volume as a downstream effect seems to be negligible.\textsuperscript{32,42,44,54–60} Such a downstream effect was only seen with small “loss” volumes in two patients only when applying transthoracical ITC. It is worth mentioning that to the best of our knowledge we applied for the first time this protocol using a dye and simultaneous bronchoscopy during transthoracical approach of ITC to control this unintended effect of downstreaming and thereby optimized the application of aqueous cisplatin for ITC in a transthoracical approach. A big difference in this study compared to other studies was that we took this approach in very sick ECOG 2 patients who were not eligible for standard oncologic care procedures. Under general conditions these patients would have only received best supportive care with a survival prognosis around 3 months. Even comparing these very sick patients with the actual database UICC 7, which is referred to as ECOG 0–1 patients treated in general with full standard dose of intravenous platinum doublet schedules, it appears as if this simple and less toxic protocol is superior to standard intravenous regimens with respect to not only quality of life but as well to overall survival measured as cancer related death. For now, the technique described herein using free drug is applicable everywhere and induces relatively low costs compared to the so called personalized tumor treatment with modern drugs like tyrosine-kinase-inhibitors.

However, there is much room for optimization and further investigation into the formulations of the drugs administered in this study is warranted.\textsuperscript{36,40,51,61} First, passive or active targeting should be explored. Active targeting has the advantage that the formulation will bind locally to tumor cells and will not leak through the abnormal vascular structures. Toward this end, several efforts have been made to identify molecules that can target actively with or without an additional chemotherapy agent the tumor mutations.\textsuperscript{62} Several molecules/pathways have been investigated in lung cancer patients, such as Galectin-3 and Cyclin D1, however there are still no candidates for active targeting. This is an example where molecules and pathways, although similar in different tumors, play different roles.\textsuperscript{63} In an effort to identify new methods of sustaining drug release, co-encapsulation of magnetic Fe\textsubscript{3}O\textsubscript{4} with chemotherapeutic agents have been investigated.\textsuperscript{27,64} However, although this method of local drug entrapment is effective in small animals, it can be lethal in larger (> dogs) as a larger magnetic field is required. Also, extravasation has been observed when the drug formulation is injected superficially. Another method of drug release which is under investigation by Patrick Le Pivert (Interventional Drug Delivery Systems and Strategies [ID2S2], Medical Cryogenics, Jupiter, FL, USA) is intratumoral drug injection while simultaneously freezing tissue locally.\textsuperscript{40} Another method for temporary local entrapment based on passive transportation is the addition of epinephrine with the cisplatin drug formulation.\textsuperscript{66} The pH release system has also been investigated with chemotherapy, the principal theory being that at a low pH (<6.5; acidic environment) the formulated complex releases the encapsulated drug.\textsuperscript{27} In the study by Callahan et al,\textsuperscript{46} for the first time a pH responsive genetically encoded drug release nanoparticle system was engineered. This pH delivery system is designed to release drug formulations in the mildly acidic environment that prevails in the extracellular matrix (ECM) of many solid tumors. Temperature-sensitive gels as an intratumoral sustain release system were also investigated (β-Lapachone). This formulation can be combined in a drug formulation complex and act as the trigger for the drug release.\textsuperscript{28}

Furthermore, a new methodology for evaluating drug formulations for intratumoral delivery has to be pursued. Specifically, as previously presented in gene therapy studies, prediction models for drug diffusion within the tumor have to be established before initiation of drug administration.\textsuperscript{67} The ITASSER (\url{http://zhanglab.ccmb.med.umich.edu}, Ann Arbor, MI, USA) software is an established evaluation method with many applications that has been used in previous studies.\textsuperscript{67,68}

Moreover, several other studies were performed using the ITASSER methodology; however, they were all implemented in other organs, but they did demonstrate both efficiency and safety.\textsuperscript{30} Radioactive wires have been applied with or without the combination of a chemotherapy agent. These studies used nanoparticles for better tumor penetration and diffusion (Table 4).\textsuperscript{42,44,64,69,70} In these studies, it was observed that healthy tissue was not affected by this therapy. In a study by Watson et al\textsuperscript{70} an ultrasound methodology was investigated to efficiently deliver nanoparticles in epithelial and epithelial-mesenchymal transition tumors. Nanoparticles have also been used in association with thermal ablation as a method for enhancing drug delivery/diffusion within the tumor and to enhance local cytotoxicity.\textsuperscript{29} Intratumoral gene therapy was also investigated with or without the addition of a chemotherapy agent and or radiotherapy.\textsuperscript{44,67,71–73} In a gene therapy study by Hanna et al\textsuperscript{72} the methodology of intratumoral injection was presented making this study an example for others to follow. In these studies, it was observed that larger particles have a higher probability of being absorbed by macrophages. New photo-absorbent agents have also been tested as intratumoral therapy. Indocyanine green was conjugated with phospholipid-polyethylene glycol-monoclonal antibody (PL-PEG-mAb in order to create a formulation with slow clearance times.
Table 4 Intratumoral studies using different approaches

<table>
<thead>
<tr>
<th>Author</th>
<th>Methodology</th>
<th>Subjects</th>
<th>Cancer cells/tissue</th>
<th>Response</th>
<th>Nanoparticles</th>
<th>Carriers</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Horev-Drori et al</td>
<td>224-Ra-loaded wires plus gemcitabine/5-FU</td>
<td>In vitro/in vivo</td>
<td>Pancreas</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>30</td>
</tr>
<tr>
<td>Xie et al</td>
<td>64-Cu-nanoshells</td>
<td>Nude rats</td>
<td>Head-neck</td>
<td>✓</td>
<td>✓</td>
<td>Nanoshells</td>
<td>42</td>
</tr>
<tr>
<td>Hecht et al</td>
<td>TNFerade (AdGVEGR.TNF.11D)</td>
<td>Patients</td>
<td>Pancreas</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>71</td>
</tr>
<tr>
<td>Govindarajan et al</td>
<td>TMAF</td>
<td>In vitro/in vivo</td>
<td>Breast-ovarian</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>67</td>
</tr>
<tr>
<td>Lin et al</td>
<td></td>
<td>Review</td>
<td>Review</td>
<td>Review</td>
<td>Lipid nanoparticles</td>
<td>Review</td>
<td>41</td>
</tr>
<tr>
<td>Cunha-Filho et al</td>
<td>/-Lapachone</td>
<td>In vitro/in vivo</td>
<td>Intratumoral implant</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>28</td>
</tr>
<tr>
<td>Zheng et al</td>
<td>ICG-PL-PEG-mAb</td>
<td>In vitro/in vivo</td>
<td>U87-MG human glioblastoma cancer cells</td>
<td>✓</td>
<td>ICG-PL-PEG-mAb</td>
<td>PL-PEG</td>
<td>74</td>
</tr>
<tr>
<td>Luo et al</td>
<td>Core-loaded fibers with hydroxycamptothecin</td>
<td>In vitro/in vivo</td>
<td>H22 hepatoma cells</td>
<td>✓</td>
<td>–</td>
<td>Fibers</td>
<td>75</td>
</tr>
<tr>
<td>Tsuda et al</td>
<td>Propionibacterium acnes</td>
<td>In vitro/in vivo</td>
<td>B16 melanoma cell line</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>77</td>
</tr>
<tr>
<td>Oh et al</td>
<td>SLC-Fc, CpG-ODN</td>
<td>In vitro/in vivo</td>
<td>B16F10 murine melanoma model</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>78</td>
</tr>
<tr>
<td>Yang et al</td>
<td>Hu14.18-IL-2</td>
<td>In vitro/in vivo</td>
<td>NXS2 neuroblastoma Cell line</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>79</td>
</tr>
<tr>
<td>Peiris et al</td>
<td>Three nanoparticle magnetic chain with doxorubicin</td>
<td>In vitro/in vivo</td>
<td>MAT B III tumor-bearing animals</td>
<td>✓</td>
<td>Nano chain magnetic particles</td>
<td>–</td>
<td>64</td>
</tr>
<tr>
<td>Hanna et al</td>
<td>BC-819</td>
<td>In vitro/in vivo</td>
<td>Pancreas</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>72</td>
</tr>
<tr>
<td>Liu et al</td>
<td>mPEG-PCL-Docetaxel</td>
<td>In vitro/in vivo</td>
<td>H22 hepatoma cells</td>
<td>✓</td>
<td>mPEG-PCL</td>
<td>Poly(3-caprolactone)</td>
<td>69</td>
</tr>
<tr>
<td>Luo et al</td>
<td>PELA fibers plus hydroxycamptothecin</td>
<td>In vitro/in vivo</td>
<td>H22 hepatoma cells</td>
<td>✓</td>
<td>PELA</td>
<td>Poly(3-caprolactone)</td>
<td>76</td>
</tr>
<tr>
<td>Geletneky et al</td>
<td>Parvovirus H-1</td>
<td>In vivo</td>
<td>Glioblastoma multiforme</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>73</td>
</tr>
<tr>
<td>Zhao et al</td>
<td>NLP-PEG, CLP-PEG plus DOX</td>
<td>In vitro/in vivo</td>
<td>H22 hepatoma cells</td>
<td>✓</td>
<td>DOX-NLPS, DOX-CLPs, DOX-NLP-PEG, DOX-CLP-PEG</td>
<td>Cationic liposomes, nano-lipid particles</td>
<td>44</td>
</tr>
<tr>
<td>Ahmed et al</td>
<td>Nanoparticles and thermal ablation</td>
<td>Review</td>
<td>Review</td>
<td>Review</td>
<td>Review</td>
<td>Review</td>
<td>29</td>
</tr>
<tr>
<td>Betting et al</td>
<td>CpG plus rituximab/cyclophosphamide</td>
<td>In vitro/in vivo</td>
<td>B-cell lymphoma</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>81</td>
</tr>
<tr>
<td>Son et al</td>
<td>Dendritic cells plus cyclophosphamide/irradiation</td>
<td>In vitro/in vivo</td>
<td>CT-26 colon</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>83</td>
</tr>
<tr>
<td>Galili</td>
<td>Anti-gal human antibody</td>
<td>Review</td>
<td>Review</td>
<td>Review</td>
<td>Review</td>
<td>Review</td>
<td>84</td>
</tr>
<tr>
<td>Hamalukic et al</td>
<td>HMG-CoA reductase inhibitor lovastatin</td>
<td>In vitro/in vivo</td>
<td>HT29 human colon</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>85</td>
</tr>
<tr>
<td>Raut et al</td>
<td>Soraferib</td>
<td>Patients</td>
<td>Refractory sarcomas</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>86</td>
</tr>
<tr>
<td>Werner et al</td>
<td>Cisplatin/epiniphrine</td>
<td>Patients</td>
<td>Head neck</td>
<td>✓</td>
<td>–</td>
<td>–</td>
<td>65</td>
</tr>
</tbody>
</table>

**Abbreviations:** FU, fluorouracil; PEG, polyethylene glycol; U-87-MG, human glioblastoma-astrocytoma, epithelial-like cell line; DOX, doxorubicin; B16, melanoma cell line; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; PL, polyactic; H22, hepatoma cells; CT-26, colon carcinoma cell line; ODN, oligodeoxynucleotide; HT29, human colon carcinoma cell lines; B16F10, murine metastatic melanoma in the tails of C57BL/6 mice; TNFerade, a replication-deficient adenoviral vector that expresses tumor necrosis factor-α (TUMOR NECROSIS FACTOR-α); BC-819, a plasmid comprised of the H19 gene regulatory sequences; mPEG-PCL, poly(caprolactone); PELA, poly(DL-lactide); SLC-Fe, secondary lymphoid tissue chemokine-Fc; CLP, cationic liposomes; NLP, neutral liposomes; ICG-PL-PEG-mAb, Indocyanine green-poly-L-lactic/polyethylene glycol-integrin α(v)β(3) monoclonal antibody; AdGVEGR.TNF.11D, a replication-deficient adenoviral vector that expresses tumor necrosis factor-α (TUMOR NECROSIS FACTOR-α); Hu14.18-IL-2, an immunocytokine consisting of human IL-2 linked to hu4.18 mAb, which recognizes the GD2 disialoganglioside; NXS2, neuroblastoma cell line; MAT B, animals (inoculated with Mat B-III-uPAR cells).
This drug formulation has numerous applications for several cancer types. Moreover, fibers bearing chemotherapy agents were constructed for intratumoral therapy and were evaluated for their pharmacokinetic profile and efficiency in vitro and in vivo. The fibers presented efficient tumor control and a correlation with radiolabelled coils was established.

Immunotherapy as intratumoral therapy has also been investigated: (a) Propionibacterium acnes induces immune-stimulation by increasing interleukin-12, tumor necrosis factor-α, and interferon-γ; (b) secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine-oligodeoxynucleotide were used to mobilize lymphocytes and dendritic cells and increased the infiltration of CD4+ T-cells and CD11c+ cells in the tumor mass with observed reduction in tumor mass; (c) hu14.18-interleukin-2 administration resulted in increased natural killer (NK) group 2, member D receptors on intratumoral NKG2A/C/E; (d) OK-432 efficiently suppressed metastatic squamous cell carcinoma lesion by inducing interferon-γ and tumor necrosis factor-α; (e) pre-treatment with cyclophosphamide and oligodeoxynucleotides plus rituximab enhanced immune activation against tumor cells and reduced tumor evolution; (f) dendritic cells and dendritic cells plus cyclophosphamide or paclitaxel at low doses enhanced immune system activation; (g) anti-gal antibody injection. Furthermore, several biomarkers were used specifically in intratumoral therapies as independent predictive factors, such as T cells and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an inhibitor of lovastatin, as a formulation that blocks local metastasis after irradiation.

Recently, sorafenib, a multi-targeted tyrosine kinase inhibitor, was used in an effort to modify interstitial fluid pressure (IFP) and vascular density. It was observed that sorafenib and imatinib both decreased IFP, increased vascular endothelial growth factor receptor-2, and, consequently, disease control that intratumoral chemotherapy should be considered for the following uses: a. As a debulking tool in central NSCLC with a high efficacy rate of >75% after four weekly sessions of ITC; demonstrated efficacy in 378 published patients including this trial over two decades in different countries; b. As an adjunct to standard therapies even now in healing trials in PS2-patients with central obstructive palliative NSCLC; c. Five studies, including this trial using ITC as an adjunct to different standard therapies, are observational studies using different modalities (to the best knowledge Phase IIb), but they have shown in 68 patients with NSCLC IIIa–IV unexpected median survival with an improvement of 21%–78% compared to UICC 7 data (4–6 months in total); d. Direct treatment with ITC (cisplatin 0.5%–1%) of central tumor mass and involved lymph nodes by EBUS-TBND is possible without severe adverse effects; e. Direct treatment with ITC (para-toluenesulfonamide) of peripheral nodules in combination with standard carboplatin doublet chemotherapy shows very promising results; and f. ITC as an adjuvant local procedure in combination with standard, timely separated intravenous protocols should be tested against adjuvant radiotherapy especially in regards to (reduced) toxicity and survival.

Disclosure
The authors report no conflicts of interest in this work.

References


